Navigation Links
Genes affect weight loss drug effectiveness
Date:9/30/2008

What:

A study conducted by researchers at Mayo Clinic shows that obese patients with specific genetic makeup had enhanced response to the weight loss drug sibutramine, while others who lack these genetic factors lost little or no weight.

The findings are published in the October issue of Gastroenterology (www.gastrojournal.org).

In this randomized, double-blind, placebo-controlled study, Mayo researchers measured the impact of two different dosage levels of sibutramine (10 or 15 mg daily) combined with behavioral therapy for 12 weeks in 181 overweight or obese participants. Participants received structured behavioral therapy for weight management at four, eight and 12 weeks.

As has been previously shown in trials with this approved medication, patients who received sibutramine and behavioral therapy lost significantly more weight than those who received placebo and the same behavioral therapy. Researchers also confirmed that weight loss at four weeks was a significant predictor of weight at 12 weeks, even after adjusting for baseline weight, gender, BMI and treatment.

Researchers explored the influence on weight and body composition of specific genetic markers indicative of variation in the function of two hormones/transmitters and an intracellular protein that mediates the function of those hormones. Patients with a certain pattern of variations of the genes lost an average of 10-12 pounds over the 12-week study, and those with unfavorable variations did worse.

Who:

Dr. Michael Camilleri, a Mayo Clinic gastroenterologist and the lead author of the study, is available for interviews. Please call Amy Tieder, Mayo Clinic Public Affairs, 507-284-5005, to make arrangements.

For audio and video:

Please also see Mayo Clinic news blog (http://newsblog.mayoclinic.org/2008/09/17/genes-weight-loss-drug-effectiveness/), password, e546f1 for audio and web video from Dr. Camilleri.


'/>"/>
Contact: Amy Tieder
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Pathway links inflammation, angiogenesis and breast cancer
2. Traffic Fumes Plus Genes Boosts Kids Asthma Risk
3. New Database to Help Speed Search for Bipolar Disorder Genes
4. Is Perfect Pitch All in the Genes?
5. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
6. Genes Boost Risk for Rheumatoid Arthritis, Lupus
7. The genes involved in rheumatoid arthritis identified
8. If you think cancer genes are simple, you dont know JAK
9. Test for lung cancer looks for discomforting quiet among protective genes
10. Hushed Genes Might Mean Higher Lung Cancer Risk
11. EURYI project to understand how the brain wires during embryogenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... While it’s ... poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , ... medication in darkness or restricted lighting. As such, it eliminates the need to turn ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology: